BiotechTube

DSXS topical

Phase 2Completed
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Sep 2, 2016 → Oct 16, 2017

NCT ID
NCT02932878

About DSXS topical

DSXS topical is a phase 2 stage product being developed by Sun Pharmaceutical for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02932878. Target conditions include Plaque Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Plaque Psoriasis were approved

Approved (20) Terminated (6) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved
✅Topicort® (desoximetasone) Topical Spray, 0.25%Sun PharmaceuticalApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02932878Phase 2Completed
NCT02932891Phase 2Completed

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43
alefaceptAstellas PharmaApproved
35
AlefaceptAstellas PharmaApproved
43
Halobetasol PropionateSun PharmaceuticalPhase 2
27
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXSSun PharmaceuticalPhase 2
35
Halobetasol Topical LotionSun PharmaceuticalApproved
35
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
40
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
35
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
40
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
40
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32
Topical TA-102 A + Topical TA-102 B + Topical TA-102 C + Topical TA-102 D + Topical TA-102 ESun PharmaceuticalPhase 1
29